# SELLAS Life Sciences Group, Inc.: overview SLS · Nasdaq · CIK 1390478 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sls.md) · [Financials](/companies/sls/financials.md) · [Filings](/companies/sls/filings.md) · [Insiders](/companies/sls/insiders.md) Latest reported revenue: [$0](/filings/0001390478-24-000004.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 28, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001390478-24-000004). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.10)](/filings/0001390478-25-000020.md) | not reported | [(0.07)](/filings/0001390478-26-000008.md) | [(0.07)](/filings/0001390478-26-000012.md) | [(0.06)](/filings/0001390478-25-000020.md) | not reported | [(0.05)](/filings/0001390478-26-000008.md) | [(0.05)](/filings/0001390478-26-000012.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [7,600](/filings/0001390478-23-000005.md) | [1,000](/filings/0001390478-24-000004.md) | [0.0](/filings/0001390478-24-000004.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(332.8%)](/filings/0001390478-23-000005.md) | [(4195.0%)](/filings/0001390478-24-000004.md) | not reported | not reported | not reported | | Net margin | % | [(272.4%)](/filings/0001390478-23-000005.md) | [(4130.1%)](/filings/0001390478-24-000004.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.34)](/filings/0001390478-23-000005.md) | [(2.13)](/filings/0001390478-24-000004.md) | [(1.34)](/filings/0001390478-25-000003.md) | [(0.50)](/filings/0001390478-26-000003.md) | [(0.25)](/filings/0001390478-26-000003.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sls/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $222.4m | 15,070,302 | | Added +2,871,892 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $191.8m | 12,996,558 | | Added +4,600,202 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $121.4m | 8,226,105 | | Added +700,176 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $105.6m | 7,157,200 | Call | Reduced −466,900 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $72.1m | 4,884,175 | | Added +971,569 | | [Anson Funds Management LP](/funds/1491072.md) | 2026-06-30 | $66.4m | 4,500,000 | | New +4,500,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $64.2m | 4,346,700 | Call | Reduced −21,500 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $61.8m | 4,189,200 | Put | Added +3,228,800 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $33.3m | 2,258,400 | Put | Added +1,808,600 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $31.9m | 2,161,099 | | Added +698,293 | ## Recent filings [All 1,201 filings](/companies/sls/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:07 ET | [8-K](/filings/0001390478-26-000013.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001390478-26-000013 | | 2026-08-11 | 16:01 ET | [10-Q](/filings/0001390478-26-000012.md) | Quarterly report, period 2026-06-30 | 0001390478-26-000012 | | 2026-07-27 | 16:35 ET | [8-K](/filings/0001104659-26-087110.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-087110 | | 2026-06-25 | 08:30 ET | [8-K](/filings/0001104659-26-077556.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-077556 | | 2026-06-18 | 16:30 ET | [8-K](/filings/0001104659-26-075775.md) | 5.07 Shareholder vote results | 0001104659-26-075775 | | 2026-06-02 | 08:30 ET | [8-K](/filings/0001104659-26-069251.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-069251 | | 2026-05-12 | 16:07 ET | [8-K](/filings/0001390478-26-000009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001390478-26-000009 | | 2026-05-12 | 16:01 ET | [10-Q](/filings/0001390478-26-000008.md) | Quarterly report, period 2026-03-31 | 0001390478-26-000008 | | 2026-04-23 | 16:09 ET | [DEF 14A](/filings/0001104659-26-047693.md) | Proxy statement, period 2026-06-16 | 0001104659-26-047693 | | 2026-03-19 | 16:08 ET | [8-K](/filings/0001390478-26-000004.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001390478-26-000004 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001390478-26-000003.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1390478 - Tickers: SLS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:29 ET. No prices; not investment advice.